Improving access to an important MS treatment

In MENA, many patients do not have access to the range of healthcare solutions that are available elsewhere in the world.

Through discussions with key stakeholders, we identified that an important medicine, dimethyl fumarate (DMF), used for the treatment of multiple sclerosis (MS) was not available in many MENA countries. This year, we became the first company to launch this product in two markets and we expect to launch it in a further eight markets by the end of 2020.

We are engaging with healthcare professionals to help raise awareness and develop the skills required in the treatment and diagnosis of MS. Many of these physicians helped advocate for fast-track approval of Hikma’s DMF to speed up access to this critical medicine for their patients.

Launching dimethyl fumarate across MENA

1. Pending regulatory approval

quotemark graphic

Multiple sclerosis is a progressive disease which we have to stop. DMF represents a very suitable option for patients with moderate disease activity."

Dr Nevin Mohieldin Professor of Neurology, Cairo University

You may also like


Working with our customers to address critical shortages


Improving patient’s access to ritonavir